Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Aflibercept (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours
- Focus Therapeutic Use
- 11 Aug 2023 Status changed from active, no longer recruiting to completed.
- 14 Oct 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 12 Jan 2021 Planned primary completion date changed from 1 Jun 2020 to 1 Mar 2021.